All In Biotech

Drug Trial Radar · NCT01408069

Non-Inferiority Comparison of Migrane® Versus Parcel ® For Treatment of Tensional Cephaleia

Multicentric, Randomizade, Double Blind, Double Dummy To Non-Inferiority Comparison Of Migrane® Versus Parcel ® For Treatment Of Tensional Cephaleia

Last checked: Nov 20, 2026Latest source record: Feb 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

WithdrawnPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Withdrawn

Enrollment

0

Actual

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
EMSIndustry
Sponsor type
Industry
First posted
Aug 3, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different associations of drugs in the treatment of patients diagnosed with tensional-type headache in accordance with International Headache Society guidelines.

Conditions

  • Tensional-type Headache

Interventions

  • MIGRANEDrug

    1 to 2 tablets(ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg)

  • PARCELDrug

    1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of treatment in relieve headache symptoms.Time frame: 1 hour

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.